(RTTNews) - Dr. Reddy's Laboratories Ltd. (DRREDDY, RDY), on Wednesday, announced the launch of over-the-counter or OTC Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren Arthritis ...
Perrigo announced that the FDA has approved the abbreviated New Drug Application for its over-the-counter diclofenac sodium topical gel 1% for the temporary relief of arthritis pain in the hand, wrist ...
HONOLULU, HI—Minimal systemic distribution of topical diclofenac sodium gel resulted in a lower incidence of major or moderate drug-drug interactions associated with oral diclofenac and reduced the ...
Novartis Corporation Voltaren Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis PARSIPPANY, N.J., Oct. 22 -- Voltaren(R) ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal’ or the “Company”) and PL Developments (PLD) today announced that they have commenced shipments of store brand ...
First US approval for a prescription NSAID (non-steroidal anti-inflammatory drug) treatment that can be applied directly to site of osteoarthritis pain Voltaren Gel is the only prescription topical ...
With the lapse of patent protection for Voltaren in many key markets, Novartis is taking the usual route to extending product life cycle—new formulations. While marketing efforts for this one aren’t ...
Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
In this single-site phase III randomized double-blind trial, we enrolled patients with breast or GI cancer who were planned to receive capecitabine-based treatment. Participants were randomly assigned ...